Table 2.
The results of univariate analysis of overall survival (n = 196). Values are mean ± SD or n (%)
| Covariates | Statistics | Hazard ratio (95% CIs), p-value |
|---|---|---|
| Age, years | 60.44 ± 10.14 | 1.01 (0.99, 1.04) 0.1624 |
| Female | 70 (35.71%) | 0.60 (0.38, 0.92) 0.0201 |
| Never smoker | 69 (35.20%) | 1.08 (0.72, 1.64) 0.7038 |
| Hypertension | 66 (33.67%) | 1.11 (0.74, 1.68) 0.6070 |
| Leukocyte, 109/L | 7.07 ± 2.57 | 1.04 (0.96, 1.11) 0.3226 |
| Neutrophil, 109/L | 4.97 ± 2.21 | 1.05 (0.96, 1.14) 0.2963 |
| Lymphocyte, 109/L | 1.31 ± 0.55 | 0.90 (0.63, 1.28) 0.5478 |
| Platelets, 109/L | 256.67 ± 98.46 | 1.00 (1.00, 1.00) 0.2259 |
| Albumin, g/L | 41.84 ± 4.65 | 0.92 (0.88, 0.95) < 0.0001 |
| Globulin, g/L | 28.51 ± 4.97 | 1.01 (0.97, 1.05) 0.7345 |
| AGR | 1.52 ± 0.33 | 0.47 (0.26, 0.84) 0.0105 |
| ALK rearrangement | ||
| No | 136 (69.39%) | 1.0 |
| Yes | 3 (1.53%) | 0.89 (0.21, 3.71) 0.8743 |
| Unknown | 57 (29.08%) | 1.00 (0.64, 1.55) 0.9866 |
| EGFR mutation | ||
| No | 83 (42.35%) | 1.0 |
| Yes | 57 (29.08%) | 0.90 (0.56, 1.46) 0.6706 |
| Unknown | 56 (28.57%) | 0.92 (0.57, 1.50) 0.7518 |
| Histology | ||
| Adenocarcinoma | 124 (63.27%) | 1.0 |
| Squamous cell carcinoma | 47 (23.98%) | 0.89 (0.55, 1.45) 0.6430 |
| Others | 25 (12.76%) | 0.81 (0.43, 1.53) 0.5158 |
| Tumor stage | ||
| III | 30 (15.31%) | 1.0 |
| IV | 166 (84.69%) | 1.67 (0.91, 3.07) 0.0964 |
| ECOG PS score | ||
| 0 | 136 (69.39%) | 1.0 |
| 1 | 60 (30.61%) | 1.17 (0.75, 1.82) 0.4810 |
| Number of metastases | ||
| <3 | 153 (78.06%) | 1.0 |
| ≥3 | 43 (21.94%) | 1.49 (0.94, 2.37) 0.0886 |
| Number of previous treatment lines | ||
| <3 | 107 (54.59%) | 1.0 |
| ≥3 | 89 (45.41%) | 1.08 (0.73, 1.61) 0.6975 |
| Number of previous chemotherapy lines | ||
| ≤2 | 153 (78.06%) | 1.0 |
| >2 | 43 (21.94%) | 0.93 (0.58, 1.49) 0.7676 |
| Previous targeted therapy | 69 (35.20%) | 1.15 (0.76, 1.74) 0.5034 |
| Previous radiotherapy | 35 (17.86%) | 0.72 (0.42, 1.24) 0.2364 |
| Previous immunotherapy | 32 (16.33%) | 1.08 (0.63, 1.84) 0.7910 |
| Anlotinib monotherapy | 156 (79.59%) | 0.93 (0.55, 1.59) 0.7998 |